Portfolio company
Convergent Genomics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops non-invasive urine-based genomic tests to detect and monitor bladder cancer for clinicians and their patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Decipher Biosciences
The company develops genomic tests and machine learning algorithms for urologic cancers to assist physicians and patients with therapy selection and risk stratification.
Predicta Biosciences
This company develops blood-based genomic diagnostic tests for clinicians and pharmaceutical partners to monitor and treat blood cancers.
Cambridge Cancer Genomics
This company develops precision oncology software for clinicians to monitor treatment response and detect cancer relapse using genomic data and blood samples.
Infiniplex
This company develops liquid biopsy solutions using blood tests to monitor genetic biomarkers for cancer screening and precision oncology decisions for healthcare providers.
Foresight Diagnostics
This company develops liquid biopsy tests to detect minimal residual disease in cancer patients for biopharmaceutical companies and healthcare providers.
Veracyte
This company develops genomic tests and diagnostic tools to help clinicians and patients make informed treatment decisions for various types of cancer.
Avant Genomics
The company develops an automated platform for liquid biopsy sample preparation to assist clinical laboratories in cancer detection and monitoring.
Genomill Health
Genomill Health develops targeted sequencing technology for liquid biopsies to assist clinical laboratories and pharmaceutical companies with precision cancer diagnostics.